RCUS
Price
$8.40
Change
+$0.29 (+3.58%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
858.73M
19 days until earnings call
XOMA
Price
$24.06
Change
+$0.72 (+3.08%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
276.71M
19 days until earnings call
Ad is loading...

RCUS vs XOMA

Header iconRCUS vs XOMA Comparison
Open Charts RCUS vs XOMABanner chart's image
Arcus Biosciences
Price$8.40
Change+$0.29 (+3.58%)
Volume$8.83K
Capitalization858.73M
XOMA Royalty
Price$24.06
Change+$0.72 (+3.08%)
Volume$207
Capitalization276.71M
RCUS vs XOMA Comparison Chart
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. XOMA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongBuy and XOMA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (RCUS: $8.11 vs. XOMA: $23.34)
Brand notoriety: RCUS and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 237% vs. XOMA: 68%
Market capitalization -- RCUS: $858.73M vs. XOMA: $276.71M
RCUS [@Biotechnology] is valued at $858.73M. XOMA’s [@Biotechnology] market capitalization is $276.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 5 TA indicator(s) are bullish while XOMA’s TA Score has 4 bullish TA indicator(s).

  • RCUS’s TA Score: 5 bullish, 3 bearish.
  • XOMA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than XOMA.

Price Growth

RCUS (@Biotechnology) experienced а +3.31% price change this week, while XOMA (@Biotechnology) price change was +13.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

RCUS is expected to report earnings on Jul 31, 2025.

XOMA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($859M) has a higher market cap than XOMA($277M). XOMA YTD gains are higher at: -11.187 vs. RCUS (-45.534). XOMA has higher annual earnings (EBITDA): -18.71M vs. RCUS (-269M). RCUS has more cash in the bank: 978M vs. XOMA (143M). RCUS has less debt than XOMA: RCUS (60M) vs XOMA (119M). RCUS has higher revenues than XOMA: RCUS (258M) vs XOMA (9.71M).
RCUSXOMARCUS / XOMA
Capitalization859M277M310%
EBITDA-269M-18.71M1,437%
Gain YTD-45.534-11.187407%
P/E RatioN/AN/A-
Revenue258M9.71M2,657%
Total Cash978M143M684%
Total Debt60M119M50%
FUNDAMENTALS RATINGS
RCUS vs XOMA: Fundamental Ratings
RCUS
XOMA
OUTLOOK RATING
1..100
1323
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
9294
PRICE GROWTH RATING
1..100
8956
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (1) in the Biotechnology industry is somewhat better than the same rating for RCUS (57) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew somewhat faster than RCUS’s over the last 12 months.

XOMA's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as XOMA (94) in the Biotechnology industry. This means that RCUS’s stock grew similarly to XOMA’s over the last 12 months.

XOMA's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for RCUS (89) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew somewhat faster than RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as XOMA (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to XOMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSXOMA
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 21 days ago
82%
Bearish Trend 17 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PUFCX17.83N/A
N/A
PGIM Jennison Financial Services C
PNOPX106.38N/A
N/A
Putnam Sustainable Leaders A
SPFCX15.55N/A
N/A
PGIM Jennison Focused Growth C
WWICX11.34N/A
N/A
Westwood Income Opportunity C
RPNCX9.15N/A
N/A
Riverpark/Next Century Growth Retail

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+0.25%
ACLX - RCUS
46%
Loosely correlated
+0.81%
APGE - RCUS
43%
Loosely correlated
+2.93%
IDYA - RCUS
42%
Loosely correlated
+0.91%
ATXS - RCUS
41%
Loosely correlated
+12.55%
BCYC - RCUS
41%
Loosely correlated
-0.69%
More